How the body processes a new liver drug in different liver conditions
Part of Cancer, Lungs & breathing clinical trials.
This study tests how a new experimental drug (anecatibin) is processed differently by people with normal liver function versus those with liver disease. The goal is to understand safe dosing for people whose livers don't work as well, which helps doctors treat them better in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Weigh at least 50 kg (men) or 45 kg (women) with a healthy BMI (18–30)
- Agree to use effective birth control from screening through 6 months after the last dose
- Have stable liver health (if you have liver disease) or normal liver function (if you don't)
- Not have taken any experimental drugs in the last 3 months
- Be willing and able to follow all study procedures and visit requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.